Last year, pharmaceutical giant Pfizer (NYSE: PFE) reported the highest revenue it had ever had in a single calendar year. But in 2023, the drugmaker has substantially underperformed the market, and its shares are down by 41% year to date. These two facts aren't unrelated. Pfizer generated record-breaking sales in 2021 and 2022 thanks to its coronavirus portfolio, which has lost momentum since the COVID-19 pandemic has largely receded.
Even so, investors could be underestimating Pfizer's potential. Let's find out why the healthcare giant is still worth investing in, especially at current levels.
Source Fool.com